Skip to content

Effects of Transcutaneous Vagus Nerve Stimulation on Upper Limb Motor Function and Serum NGF/BDNF Levels in Patients with Acute Ischemic Stroke

Effects of Transcutaneous Vagus Nerve Stimulation on Upper Limb Motor Function and Serum NGF/BDNF Levels in Patients with Acute Ischemic Stroke - Transcutaneous Vagus Nerve Stimulation in Acute Ischemic Stroke: Effects on Upper Limb Function and Serum NGF/BDNF

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082197
Enrollment
Unknown
Registered
2024-03-22
Start date
2024-03-30
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Real Stimulation group:1.All patients receive fundamental neurological care, including clinical pharmacotherapy, standard nursing care, and basic rehabilitation therapy. 2.The earplug of the transcuta
Sham Stimulation group:1.All patients receive fundamental neurological care, including clinical pharmacotherapy, standard nursing care, and basic rehabilitation therapy. 2.The earplug of the transcuta

Sponsors

Nanjing Drum Tower Hospital Group Suqian Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients with first-onset ischemic stroke confirmed by CT or MRI; (2) Onset of stroke within acute phase, with a duration ranging from 0.5 hours to 14 days; (3) Age between 30 and 75 years old; (4) Hemiplegia; (5) Stable vital signs, conscious, able to actively cooperate with assessment and treatment, and have good compliance; (6) Support from the patient's family and signed informed consent form.

Exclusion criteria

Exclusion criteria: (1) Concomitant peripheral nerve injury, Parkinson's disease, multiple sclerosis, and other neurological disorders; (2) Severe cognitive, speech, or mental disorders; (3) Presence of medical devices such as cardiac pacemakers or cochlear implants; (4) History of ear infection or loss, surgical history involving the vagus nerve, or vagus nerve damage; (5) Progressive decline in cardiac, pulmonary, hepatic, or renal function; (6) Bradycardia (heart rate < 60 bpm).

Design outcomes

Primary

MeasureTime frame
Fugl-Meyer rating scale for upper extremity (FMA-UE);

Secondary

MeasureTime frame
Brunnstrom Stages (Upper Limb and Hand); Modified Barthel Index. (MBI);Cytokine Levels: Measurement of Serum BDNF and NGF Levels; National Institutes of Health Stroke Scale (NIHSS);Safety Assessment: Monitoring of heart rate, blood pressure, electrocardiogram, and recording adverse reactions.;

Countries

China

Contacts

Public ContactBaoshan Xu

Nanjing Drum Tower Hospital Group Suqian Hospital

994290522@qq.com+86 187 5108 7782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026